Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
1.10T
Market cap1.10T
Price-Earnings ratio
40.19
Price-Earnings ratio40.19
Dividend yield
0.57%
Dividend yield0.57%
Average volume
2.15M
Average volume2.15M
High today
$1,195.00
High today$1,195.00
Low today
$1,164.02
Low today$1,164.02
Open price
$1,187.04
Open price$1,187.04
Volume
673.92K
Volume673.92K
52 Week high
$1,292.65
52 Week high$1,292.65
52 Week low
$783.85
52 Week low$783.85

Stock Snapshot

With a market cap of 1.1T, Eli Lilly(LLY) trades at $1,169.09. The stock has a price-to-earnings ratio of 40.19 and currently yields dividends of 0.57%.

During the trading session on 2026-10-13, Eli Lilly(LLY) shares reached a daily high of $1,195.00 and a low of $1,164.02. At a current price of $1,169.09, the stock is +0.4% higher than the low and still -2.2% under the high.

Trading activity shows a volume of 673.92K, compared to an average daily volume of 2.15M.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

The stock's 52-week range extends from a low of $783.85 to a high of $1,292.65.

LLY News

CNBC 17m
Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits - CNBC

...

Walmart to cover some GLP-1s, inhalers and insulin for employees at no cost as it expands benefits - CNBC
24/7 Wall St. 54m
Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests

Eli Lilly trades at a premium multiple, yet its revenue growth dwarfs every major pharma peer by a wide margin. Whether that gap justifies buying shares near al...

Prediction: Eli Lilly Could Have More Room to Grow Than Its Valuation Suggests
TipRanks 59m
H.C. Wainwright ‘highly enthusiastic’ on Prelude collaboration with Lilly

H.C. Wainwright reiterates a Buy rating on Prelude Therapeutics (PRLD) with an $8 price target after the company announced a clinical trial collaboration and su...

Analyst ratings

84%

of 32 ratings
Buy
84.4%
Hold
9.4%
Sell
6.3%

More LLY News

The Motley Fool 8h
Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.

Eli Lilly (LLY +0.28%) stock has soared 400% over the past five years, and though the momentum slowed in the early months of this year, it's now on the rise aga...

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued.
The Motley Fool 11h
Will Eli Lilly Do a Stock Split Before the End of 2026?

When stocks start trading north of the $1,000 mark, investors often wonder if a stock split may be coming. A stock split reduces the price of a stock, making it...

Will Eli Lilly Do a Stock Split Before the End of 2026?
The Motley Fool 18h
AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?

Deciding between AbbVie Inc. (ABBV +1.68%) and Eli Lilly & Co. (LLY +0.28%) requires balancing reliable dividend growth against high-octane metabolic drug expan...

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026?
TipRanks 2d
Eli Lilly Stock: Why Taking Profits Could Make Sense Ahead of 2027

Shares of drug maker Eli Lilly (LLY) have modestly underperformed the S&P 500 (SPY) in 2026, with large-cap U.S. stock returns increasingly driven by AI benefic...

Simply Wall St 2d
Eli Lilly Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial

Eli Lilly (NYSE: LLY) reported new exploratory data from the TOGETHER-PsO Phase 3b trial on combined Taltz and Zepbound use in adults with moderate to severe pl...

Eli Lilly Reported Broader Biomarker Effects In Phase 3b Psoriasis Trial
24/7 Wall St. 4d
Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock

Investing Eli Lilly’s Biggest Shareholder Just Filed to Sell $347 Million of Stock Lilly's largest shareholder just filed to unload nearly $350 million in stock...

Eli Lilly's Biggest Shareholder Just Filed to Sell $347 Million of Stock
24/7 Wall St. 4d
Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

Investing Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks Cantor Fitzgerald just bumped price targets on Eli Lilly, AbbVi...

Cantor Fitzgerald Lifts Price Targets on Four Pharma Giants Amid Mixed Growth Outlooks

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.